"In trying to localize and focalize the treatment on just the lesion of prostate cancer, HIFU was incredibly powerful in the sense that it really allowed you to do that with great precision," said Jennifer Linehan, MD.
As part of the Urology Times' 50th Anniversary Innovation Celebration, Jennifer Linehan, MD, discusses how high-intensity focused ultrasound (HIFU) revolutionized the way urologists treat localized prostate cancer. This techology, she emphasizes, creates another safe and effective minimally-invasive therapy for this population of patients. Linehan is an associate professor of urology and urologic oncology at the John Wayne Cancer Institute in Santa Monica, California.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.